FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2362256917> ?p ?o ?g. }

• W2362256917 endingPage "e254" @default.
• W2362256917 startingPage "e253" @default.
• W2362256917 abstract "ObjectiveRecent information provided by genetically modified mouse model has suggested that PI3K-Akt-mTOR/PTEN signaling pathway controlled primordial follicle activation in vivo. Also, PPAR gamma agonist induced PTEN expression and inhibited Akt phosphorylation in vitro. Ovary specific PPAR gamma was predominantly expressed in ovarian tissue. The aim of this study was to investigate whether PPAR gamma modulator might induce the activation and growth of primordial follicles from 5day female mouse after birth.DesignAnimal study.Materials and MethodsOvaries were collected from 5days old B6D2F1 or ICR female mouse and cultured on six well plate and insert for 10 days in vitro. Ovaries were cultured in DMEM/F12 containing BSA, ITS-X, and ascorbic acid, with or without PPAR gamma modulator for 2 days and transferred PPAR gamma modulator free medium. To evaluate the expression of PPAR gamma, PTEN, and Akt1 on mouse ovary, we performed real-time-PCR, immunohistochemistry, and western blot. Also, end of culture, ovaries were fixed 10% neutral-buffered formalin and subjected of HE staining, immunohistochemistry against Ki-67, AMH, PTEN, Akt1 and FOXO-3a, and apoptosis assay with TUNEL. Also, western blot was performed to evaluate the changes of PTEN, Akt1.ResultsThe expression of PPAR gamma, PTEN, Akt1 and FOXO3a were evaluated in ovaries from 5, 10, 15, 20 days and 8 weeks old mouse by RT-PCR. PPAR gamma was expressed in ovaries from all the ages, it increased in ovary in 20 days explosively. PTEN and Akt1 were increased in ovary form 10 Days. In PPAR gamma antagonist treated ovaries, PTEN was decreased and Akt1 was activated. Also nuclear exclusion of FOXO3a was observed in oocytes of primordial follicles at 6hr treatment with PPAR gamma antagonist. AMH expression was observed in PPAR gamma antagonist treated ovaries, but was not in PPAR gamma agonist. After 12 days culture, increases of ovarian sizes of PPAR gamma antagonist treated groups were observed as compare to non-treated or PPAR gamma agonist treatment.ConclusionsFrom these result, PPAR gamma may participate primordial follicle activation and further development, possibly mediated in part of PI3K-PTEN signaling pathway in vitro. Generation of activated primordial follicle in cancer treatment patients, or other infertile women may allow fertility preservation. Also Production of a large number of oocytes may facilitate future derivation of embryonic stem cell for regenerative medicine. ObjectiveRecent information provided by genetically modified mouse model has suggested that PI3K-Akt-mTOR/PTEN signaling pathway controlled primordial follicle activation in vivo. Also, PPAR gamma agonist induced PTEN expression and inhibited Akt phosphorylation in vitro. Ovary specific PPAR gamma was predominantly expressed in ovarian tissue. The aim of this study was to investigate whether PPAR gamma modulator might induce the activation and growth of primordial follicles from 5day female mouse after birth. Recent information provided by genetically modified mouse model has suggested that PI3K-Akt-mTOR/PTEN signaling pathway controlled primordial follicle activation in vivo. Also, PPAR gamma agonist induced PTEN expression and inhibited Akt phosphorylation in vitro. Ovary specific PPAR gamma was predominantly expressed in ovarian tissue. The aim of this study was to investigate whether PPAR gamma modulator might induce the activation and growth of primordial follicles from 5day female mouse after birth. DesignAnimal study. Animal study. Materials and MethodsOvaries were collected from 5days old B6D2F1 or ICR female mouse and cultured on six well plate and insert for 10 days in vitro. Ovaries were cultured in DMEM/F12 containing BSA, ITS-X, and ascorbic acid, with or without PPAR gamma modulator for 2 days and transferred PPAR gamma modulator free medium. To evaluate the expression of PPAR gamma, PTEN, and Akt1 on mouse ovary, we performed real-time-PCR, immunohistochemistry, and western blot. Also, end of culture, ovaries were fixed 10% neutral-buffered formalin and subjected of HE staining, immunohistochemistry against Ki-67, AMH, PTEN, Akt1 and FOXO-3a, and apoptosis assay with TUNEL. Also, western blot was performed to evaluate the changes of PTEN, Akt1. Ovaries were collected from 5days old B6D2F1 or ICR female mouse and cultured on six well plate and insert for 10 days in vitro. Ovaries were cultured in DMEM/F12 containing BSA, ITS-X, and ascorbic acid, with or without PPAR gamma modulator for 2 days and transferred PPAR gamma modulator free medium. To evaluate the expression of PPAR gamma, PTEN, and Akt1 on mouse ovary, we performed real-time-PCR, immunohistochemistry, and western blot. Also, end of culture, ovaries were fixed 10% neutral-buffered formalin and subjected of HE staining, immunohistochemistry against Ki-67, AMH, PTEN, Akt1 and FOXO-3a, and apoptosis assay with TUNEL. Also, western blot was performed to evaluate the changes of PTEN, Akt1. ResultsThe expression of PPAR gamma, PTEN, Akt1 and FOXO3a were evaluated in ovaries from 5, 10, 15, 20 days and 8 weeks old mouse by RT-PCR. PPAR gamma was expressed in ovaries from all the ages, it increased in ovary in 20 days explosively. PTEN and Akt1 were increased in ovary form 10 Days. In PPAR gamma antagonist treated ovaries, PTEN was decreased and Akt1 was activated. Also nuclear exclusion of FOXO3a was observed in oocytes of primordial follicles at 6hr treatment with PPAR gamma antagonist. AMH expression was observed in PPAR gamma antagonist treated ovaries, but was not in PPAR gamma agonist. After 12 days culture, increases of ovarian sizes of PPAR gamma antagonist treated groups were observed as compare to non-treated or PPAR gamma agonist treatment. The expression of PPAR gamma, PTEN, Akt1 and FOXO3a were evaluated in ovaries from 5, 10, 15, 20 days and 8 weeks old mouse by RT-PCR. PPAR gamma was expressed in ovaries from all the ages, it increased in ovary in 20 days explosively. PTEN and Akt1 were increased in ovary form 10 Days. In PPAR gamma antagonist treated ovaries, PTEN was decreased and Akt1 was activated. Also nuclear exclusion of FOXO3a was observed in oocytes of primordial follicles at 6hr treatment with PPAR gamma antagonist. AMH expression was observed in PPAR gamma antagonist treated ovaries, but was not in PPAR gamma agonist. After 12 days culture, increases of ovarian sizes of PPAR gamma antagonist treated groups were observed as compare to non-treated or PPAR gamma agonist treatment. ConclusionsFrom these result, PPAR gamma may participate primordial follicle activation and further development, possibly mediated in part of PI3K-PTEN signaling pathway in vitro. Generation of activated primordial follicle in cancer treatment patients, or other infertile women may allow fertility preservation. Also Production of a large number of oocytes may facilitate future derivation of embryonic stem cell for regenerative medicine. From these result, PPAR gamma may participate primordial follicle activation and further development, possibly mediated in part of PI3K-PTEN signaling pathway in vitro. Generation of activated primordial follicle in cancer treatment patients, or other infertile women may allow fertility preservation. Also Production of a large number of oocytes may facilitate future derivation of embryonic stem cell for regenerative medicine." @default.
• W2362256917 created "2016-06-24" @default.
• W2362256917 creator A5003817471 @default.
• W2362256917 creator A5012906658 @default.
• W2362256917 creator A5016450324 @default.
• W2362256917 creator A5023733387 @default.
• W2362256917 creator A5026095740 @default.
• W2362256917 creator A5036175630 @default.
• W2362256917 creator A5046587036 @default.
• W2362256917 creator A5056765028 @default.
• W2362256917 creator A5063692305 @default.
• W2362256917 creator A5074284582 @default.
• W2362256917 creator A5088669412 @default.
• W2362256917 date "2015-09-01" @default.
• W2362256917 modified "2023-09-27" @default.
• W2362256917 title "Artificial primordial follicles activation by peroxisome proliferator-activated receptor gamma modulator on neonatal mouse ovary in vitro" @default.
• W2362256917 doi "https://doi.org/10.1016/j.fertnstert.2015.07.798" @default.
• W2362256917 hasPublicationYear "2015" @default.
• W2362256917 type Work @default.
• W2362256917 sameAs 2362256917 @default.
• W2362256917 citedByCount "0" @default.
• W2362256917 crossrefType "journal-article" @default.
• W2362256917 hasAuthorship W2362256917A5003817471 @default.
• W2362256917 hasAuthorship W2362256917A5012906658 @default.
• W2362256917 hasAuthorship W2362256917A5016450324 @default.
• W2362256917 hasAuthorship W2362256917A5023733387 @default.
• W2362256917 hasAuthorship W2362256917A5026095740 @default.
• W2362256917 hasAuthorship W2362256917A5036175630 @default.
• W2362256917 hasAuthorship W2362256917A5046587036 @default.
• W2362256917 hasAuthorship W2362256917A5056765028 @default.
• W2362256917 hasAuthorship W2362256917A5063692305 @default.
• W2362256917 hasAuthorship W2362256917A5074284582 @default.
• W2362256917 hasAuthorship W2362256917A5088669412 @default.
• W2362256917 hasBestOaLocation W23622569171 @default.
• W2362256917 hasConcept C126322002 @default.
• W2362256917 hasConcept C127078168 @default.
• W2362256917 hasConcept C134018914 @default.
• W2362256917 hasConcept C16685009 @default.
• W2362256917 hasConcept C170493617 @default.
• W2362256917 hasConcept C185592680 @default.
• W2362256917 hasConcept C187345961 @default.
• W2362256917 hasConcept C202751555 @default.
• W2362256917 hasConcept C2778324911 @default.
• W2362256917 hasConcept C2910266098 @default.
• W2362256917 hasConcept C55493867 @default.
• W2362256917 hasConcept C71924100 @default.
• W2362256917 hasConcept C86803240 @default.
• W2362256917 hasConcept C95444343 @default.
• W2362256917 hasConceptScore W2362256917C126322002 @default.
• W2362256917 hasConceptScore W2362256917C127078168 @default.
• W2362256917 hasConceptScore W2362256917C134018914 @default.
• W2362256917 hasConceptScore W2362256917C16685009 @default.
• W2362256917 hasConceptScore W2362256917C170493617 @default.
• W2362256917 hasConceptScore W2362256917C185592680 @default.
• W2362256917 hasConceptScore W2362256917C187345961 @default.
• W2362256917 hasConceptScore W2362256917C202751555 @default.
• W2362256917 hasConceptScore W2362256917C2778324911 @default.
• W2362256917 hasConceptScore W2362256917C2910266098 @default.
• W2362256917 hasConceptScore W2362256917C55493867 @default.
• W2362256917 hasConceptScore W2362256917C71924100 @default.
• W2362256917 hasConceptScore W2362256917C86803240 @default.
• W2362256917 hasConceptScore W2362256917C95444343 @default.
• W2362256917 hasIssue "3" @default.
• W2362256917 hasLocation W23622569171 @default.
• W2362256917 hasOpenAccess W2362256917 @default.
• W2362256917 hasPrimaryLocation W23622569171 @default.
• W2362256917 hasRelatedWork W1976883865 @default.
• W2362256917 hasRelatedWork W2047192070 @default.
• W2362256917 hasRelatedWork W2067382803 @default.
• W2362256917 hasRelatedWork W2096769852 @default.
• W2362256917 hasRelatedWork W2121614730 @default.
• W2362256917 hasRelatedWork W2296459635 @default.
• W2362256917 hasRelatedWork W2316296538 @default.
• W2362256917 hasRelatedWork W2348701128 @default.
• W2362256917 hasRelatedWork W2392645372 @default.
• W2362256917 hasRelatedWork W4230870671 @default.
• W2362256917 hasVolume "104" @default.
• W2362256917 isParatext "false" @default.
• W2362256917 isRetracted "false" @default.
• W2362256917 magId "2362256917" @default.
• W2362256917 workType "article" @default.